Capital increase of Bavarian Nordic A/S following the exercise of employee stock warrants

Bavarian Nordic A/S

COPENHAGEN, Denmark, May 23, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the share capital of the company has been increased by a nominal amount of DKK 63,370 following the exercise of warrants by employees.

The capital increase was carried out without pre-emption rights for the existing shareholders of the Company or others. A total of 6,337 new shares were subscribed for in cash at DKK 142.00 per share of DKK 10 nominally. The total proceeds from the capital increase accruing to Bavarian Nordic A/S amount to DKK 0.9 million.

The new shares, which will rank pari passu in all respects with the existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as practicable.

After the capital increase, the total nominal value of the share capital of Bavarian Nordic A/S is DKK 704,792,720, consisting of 70,479,272 shares with a nominal value of DKK 10 each, corresponding to 70,479,272 votes.

The revised Articles of Association will be published separately and will then be available on the Company’s website.

The content of this announcement does not affect the Company’s expectations regarding financial results for 2022.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company focused on developing, manufacturing and marketing life-saving vaccines. We are a world leader in smallpox vaccines and have long provided the US government with a non-replicating smallpox vaccine, which has been approved by the FDA, also for protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio also contains market-leading vaccines against rabies and tick-borne encephalitis. Through our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unleashing the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also engaged in the development of a next-generation COVID-19 vaccine. For more information, visit

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are beyond our control, that could cause actual results to differ materially from those discussed in the forward-looking statements. Forward-looking statements include statements regarding our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of publication, except as required by law.

Europe: Rolf Sass Sørensen, Vice President Investor Relations, tel. : +45 61 77 47 43
United States: Graham Morrell, Paddock Circle Advisors, [email protected]Such. : +1 781 686 9600

Company announcement no. 19 / 2022